A phase II clinical trial of ZD1839 (Iressa™) in combination with docetaxel as first-line treatment in patients with advanced breast cancer

Investigational New Drugs

Volumn 25, Issue 6, 2007, Pages 545-551

  Dennison, Sheri K ^a   Jacobs, Samuel A ^b,c   Wilson, John W ^b   Seeger, Janell ^b,d   Cescon, Terrence P ^b,e   Raymond, Jane M ^b,f   Geyer, Charles E ^b   Wolmark, Norman ^b,f   Swain, Sandra M ^b,g  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NSABP Foundation Inc   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d Norton Cancer Institute   (United States)

^e READING HOSPITAL AND MEDICAL CENTER   (United States)

^f ALLEGHENY GENERAL HOSPITAL   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adult medical oncology; Advanced breast cancer; Chemotherapy; Clinical trials

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; GEFITINIB; QUINAZOLINE DERIVATIVE; TAXOID;

ADULT; AGED; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HUMAN; MALE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; NEUTROPENIA; PATHOLOGY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; QUINAZOLINES; TAXOIDS; TREATMENT OUTCOME;

EID: 34948820698     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-007-9055-6     Document Type: Article

References (39)

1. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ (2002) Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2:1-26
2. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104:1742-1750 (Pubitemid 41437440)
3. Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707-1715 (Pubitemid 32230871)
4. Pacilio C, Morabito A, Nuzzo F, Gravina A, Labonia V, Landi G, Rossi E, De Maio E, Di Maio M, D'Aiuto G, Botti G, Normanno N, Chiodini P, Gallo C, Perrone F, de Matteis A (2006) Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. Br J Cancer 94:1233-1236
5. Morris C (2002) The role of EGFR-directed therapy in the treatment of breast cancer. Breast Cancer Res Treat 75(1):S51-S55 (discussion S57-S59)
6. Dy GK, Adjei AA (2002) Novel targets for lung cancer therapy: part II. J Clin Oncol 20:3016-3028 (Pubitemid 34728897)
7. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL (1987) Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1:1398-1402 (Pubitemid 17078859)
8. Rimawi MF, Weiss HL, Bhatia P, Chamness G, Elledge RM (2006) EGFR expression in breast cancer: Association with biologic phenotype, prognosis, and resistance to adjuvant therapy. J Clin Oncol 24:513, abstract
9. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL (1994) The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 29:41-49 (Pubitemid 24104836)
10. Ferrero JM, Ramaioli A, Largillier R, Formento JL, Francoual M, Ettore F, Namer M, Milano G (2001) Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol 12:841-846 (Pubitemid 32655096)
11. Rampaul RS, Pinder SE, Wencyk PM, Nicholson RI, Blamey RW, Robertson JF, Ellis IO (2004) Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value? Clin Cancer Res 10:2578 (Pubitemid 38445721)
12. Klijn JG, Look MP, Portengen H, Alexieva-Figusch J, van PuttenWL, Foekens JA (1994) The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat 29:73-83 (Pubitemid 24104839)
13. Investigator 's Brochure, ZD1839 (2000) Data on file with AstraZeneca Pharmaceuticals
14. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063 (Pubitemid 30305105)
15. Baselga J (2002) Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. J Clin Oncol 20:2217-2219
16. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542-5551
17. Schimming R, Hunter NR, Mason KA, Milas L (1999) Inhibition of tumor neo-angiogenesis and induction of apoptosis as properties of docetaxel (taxotere). Mund Kiefer Gesichtschir 3:210-212
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
19. National Cancer Institute (1999) Common toxicity criteria v 2.0 (April 30, 1999), Cancer Therapy Evaluation Program. Bethesda, MD, National Cancer Institute, http://www.ctep.cancer.gov/forms
20. Cassella G, Berger RL (1990) Statistical inference. Duxbury, Belmont, CA, pp 416-422
21. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
22. Montero A, Fossella F, Hortobagyi G, Valero V (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6:229-239 (Pubitemid 40450714)
23. Albain K, Elledge RM, Gradishar WJ, Hayes DF, Rowinsky E, Hudis C, Pusztai L, Tripathy D, Modi S, Rubi S (2002) Open-label, phase II, multi-center trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 76:S33 (abstract 20)
24. Winer E, Cobleigh M, Dickler M, Miller KD, Fehrenbacher L, Jones C, Justice R (2002) Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib-OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat 76:S115 (abstract 445)
25. Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Guillem V, Gonzalez S, Sauleda S, Marimon I, Tabernero JM, Koehler MT, Rojo F (2005) Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23:5323-5333 (Pubitemid 46206986)
26. von Minckwitz G, Jonat W, Fasching P, du Bois A, Kleeberg U, Luck HJ, Kettner E, Hilfrich J, Eiermann W, Torode J, Schneeweiss A (2005) A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 89:165-172 (Pubitemid 40249050)
27. Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM (2004) Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 22:3080-3090 (Pubitemid 41103720)
28. Fountzilas G, Pectasides D, Kalogera-Fountzila A, Skarlos D, Kalofonos HP, Papadimitriou C, Bafaloukos D, Lambropoulos S, Papadopoulos S, Kourea H, Markopoulos C, Linardou H, Mavroudis D, Briasoulis E, Pavlidis N, Razis E, Kosmidis P, Gogas H (2005) Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat 92:1-9 (Pubitemid 40875072)
29. Agrawal A, Gutteridge E, Gee JM, Nicholson RI, Robertson JF (2005) Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer 12(1):S135-S144 (Pubitemid 41395421)
30. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA Jr., Franklin WA, Crowley J, Gandara DR (2005) Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 23:6838-6845
31. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, Tamura T (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:6829-6837
32. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B (2005) EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Path 18:1027-1033 (Pubitemid 41224492)
33. Pao W, Miller VA (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23:2556-2568
34. Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G, De Vita F, Diadema MR, Orditura M, Colantuoni G, Gridelli C, Catalano G, De Placido S, Bianco AR (2006) Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 94:1604-1609 (Pubitemid 43924921)
35. Robertson JF, Gutteridge E, Cheung KL, Owers R, Koehler MT, Hamilton L, Gee JM, and Nicholson RI (2002) Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant estrogen receptor (ER)-positive and ER-negative breast cancer: Results from a phase II study. Breast Cancer Res Treat 76:S96, abstract 357
36. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM (2004) Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 10:S346-S354
37. Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23:2445-2459 (Pubitemid 47050835)
38. Spector NL, Xia W, Burris H 3rd, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S (2005) Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23:2502-2512 (Pubitemid 47050840)
39. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743 (Pubitemid 46021510)